Featured Research

from universities, journals, and other organizations

Immunosuppressant Medication May Be Cost-effective For Dry Eye Syndrome

Date:
February 19, 2009
Source:
JAMA and Archives Journals
Summary:
A topical eye emulsion consisting of cyclosporine (a medication used to reduce transplant rejections or to treat arthritis and psoriasis) may be a cost-effective treatment for dry eye syndrome that does not respond to other therapies, according to a new report.

A topical eye emulsion consisting of cyclosporine (a medication used to reduce transplant rejections or to treat arthritis and psoriasis) may be a cost-effective treatment for dry eye syndrome that does not respond to other therapies, according to a report in the February issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

Published reports suggest that the prevalence of dry eye syndrome in older patients ranges from about 15 percent to 34 percent, according to background information in the article. "Patients with dry eye syndrome have more difficulty reading, carrying out professional work, using a computer, watching television and driving compared with those without dry eyes," the authors write. "The burden of dry eye disease from both the prevalence and patient morbidity standpoints makes this a sizeable public health dilemma."

Using data from two randomized clinical trials and Food and Drug Administration files, Melissa M. Brown, M.D., M.N., M.B.A., of the Center for Value-Based Medicine, Flourtown, and the University of Pennsylvania School of Medicine, Philadelphia, and colleagues assessed the comparative effectiveness and cost-effectiveness of eye drops containing a 0.05 percent emulsion of the drug cyclosporine for patients whose moderate to severe dry eye syndrome did not respond to conventional therapy.

When compared with eye drops containing only lubricant, the cyclosporine drops were associated with a 4.3 percent improvement in quality of life, and conferred a 7.1 percent improvement over no treatment. The total direct medical cost associated with the use of this drug was $1,834; however, because 24.5 percent of treated workers will return to full productivity as a result, there is an estimated $1,236 gain associated with treatment, reducing the net cost to $598.

Based on the authors' analysis, the cost to society for treatment with this medication was $34,953 more per quality-adjusted life year (a measure combining the quality and quantity of life) than the lubricant eye drops alone. This is well below the conventional standard of $50,000 per quality-adjusted life year that most would consider cost-effective, they note.

"The use of topical cyclosporine is a cost-effective treatment strategy for a common disease that, when unresponsive to conventional lubricant therapy, causes a marked diminution in quality of life," the authors conclude.

This study was supported by Allergan Inc.; the Center for Value-Based Medicine, Flourtown, Pa.; and the Eye Research Institute,


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Melissa M. Brown; Gary C. Brown; Heidi C. Brown; Jonathan Peet; Zachary Roth. Value-Based Medicine, Comparative Effectiveness, and Cost-effectiveness Analysis of Topical Cyclosporine for the Treatment of Dry Eye Syndrome. Archives of Ophthalmology, 2009; 127 (2): 146 DOI: 10.1001/archophthalmol.2008.608

Cite This Page:

JAMA and Archives Journals. "Immunosuppressant Medication May Be Cost-effective For Dry Eye Syndrome." ScienceDaily. ScienceDaily, 19 February 2009. <www.sciencedaily.com/releases/2009/02/090209163307.htm>.
JAMA and Archives Journals. (2009, February 19). Immunosuppressant Medication May Be Cost-effective For Dry Eye Syndrome. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2009/02/090209163307.htm
JAMA and Archives Journals. "Immunosuppressant Medication May Be Cost-effective For Dry Eye Syndrome." ScienceDaily. www.sciencedaily.com/releases/2009/02/090209163307.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins